Clinical Trial Update: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating gemcitabine hydrochloride with or without the WEE1 inhibitor adavosertib in patients with recurrent ovarian, fallopian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Adavosertib (adavosertib)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-08